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 MTLn3 cells derived from mouse mammary epithelium are known to be highly malig-
nant and are resistant to both radio- and chemo-therapy. We exposed MTLn3 cells to var-
ious doses of inorganic Arsenic trioxide (As2O3) in combination with ionizing radiation.
Cells were treated with a series of As2O3 concentrations ranging from 20 µM to 1.22 nM
for 8 hour, 24 hour and 48 hour periods. Post-treated cell proliferation was quantified by
measuring mitochondrial activity and DNA analysis. Cells exposed to radiation and As2O3
at concentration greater than 1.25 µM showed apoptosis and radiations alone treated cells
were statistically not different from the control. Hormesis was observed for As2O3 con-
centrations in the range of 0.078 µM to 0.625 µM while the combined chemo and radia-
tion treatments of the cells did not affect the hormetic effect. We have demonstrated that
As2O3 (in the presence and absence of ionizing radiation) in specific low concentrations
induced apoptosis in the otherwise chemoresistant cancer cells. This low concentration-
mediated cell death is immediately followed by a surge in cell survival. Low dosing dosime-
try is highly desirable in metronomic therapy however, it has a narrow window since necro-
sis, hormesis, apoptosis and other dose-dependent biological processes take place in this
region. Further quantifiable dosimetry is highly desired for routine clinical practice.
Keywords: Cancer cells, Arsenic trioxide, Ionizing radiation, Apoptosis, Hormesis
1 INTRODUCTION
Many patients treated for chronic diseases develop drug related
injuries. In addition to these side effects, the rising burden of chronic dis-
eases that in most cases transition into malignancies, which is one of the
major challenges faced by the health organizations throughout the world.
The chronic diseases and malignancies are routinely treated with drugs
based on the maximum tolerable dose (MTD) protocol. One of the main
issues with MTD is tissue necrosis, which results in the continuous release
of inflammatory factors into the body. Inflammatory onslaughts wreak
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havoc on the living system and over time can cause chronic diseases. The
drug induced diseases are becoming more prominent among a broad
range of patients. The cancer survival rate in patients is improved due to
advancements in therapeutic techniques, but these instances of therapy
related survival are eclipsed by the dose related side effects. Drug related
side effects in cardiovascular diseases are well documented (Senkus and
Jassem 2010). High dose treatment of breast cancer is criticized by
Zander (Zander and Kroger 2005) who argued that such treatment is
based on the acceptance of several nonrandom studies. Chemotherapy-
induced long term effects such as cardiac toxicity, secondary leukemia,
neuronal disruption, cognitive problems and sexual dysfunctions are of
great concern among physicians as well as patients and some researchers
questioned if MTD chemotherapy is an adjuvant therapy (Azim et al.
2011). Results of breast cancers in patients treated with chemo and radio-
therapy are significant which is why we need dose optimization to achieve
effective treatment while avoiding such severe effects (Cutuli et al. 2011).
Physicians are exploring the low dose therapy to offset such side effects.
Lower doses of chemotherapy and tightly blocked radiation fields may
not only decrease the risk of secondary cancers, but also provide envi-
ronmental, ecological and economic benefits.
Metronomic therapy has been suggested for older patients to avoid
severe dose related side effects (Fontana et al. 2010) but there is no low
dose standardization. On the other hand, the so called ‘low dose’ is not
low enough to avoid secondary cancers among children (O’Brien et al.
2010) and in specific cases patients treated with low doses of ionizing radi-
ation require re-irradiation (Mendenhall et al. 2008). The simple reason is
the lack of any metric which defines “low dose” per se in clinical practice.
There is also a growing trend to use smaller doses of drugs to treat
advanced cancers (Rajdev et al. 2011; Satti 2009). This technique, known
as low dose metronomic (LDM) therapy, claims equal or superior clinical
results while keeping the side effects to minimum levels. Although this
methodology is attractive, it is not without its own shortcomings. Some
studies have reported that although tolerated with minimum toxicity, side
effects such as lymphopenia have been seen in some patients (Lord et al.
2007). Problems with so called LDM have been reported with some sug-
gestions (Emmenegger et al. 2010). Tumors are heterogeneous in nature
and consisting of cells with various metastatic potential and treatment
with certain drugs may eventually develop resistance in certain popula-
tion of cells. This is due to the existence of narrow dose regions that cre-
ate apoptosis and hormesis in cells depending on the dose. Apoptosis and
hormesis are two opposing phenomenon adjacent to each other in the
dose response index, both with useful applications in medicine.
Although maximum tolerable dose and low dose metronomic both
produce cellular resistance (Gonzalez-Angulo et al. 2007; Massaccesi et al.
W. K. Raja and others
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2010; Thoenes et al. 2010), the mechanism by which the cancer cells
become resistant to LDM is entirely different from that to MTD. Studies
show that even tumors that acquire LDM resistance are still sensitive to
MTD (Emmenegger et al. 2011). A score of biological processes including
necrosis, apoptosis, hormesis, autophagy and bystander effect occur in
the narrow window of low doses. Some of these mutually exclusive bio-
logical processes such as stimulation and inhibition may happen in the
overlapping concentrations of certain drugs, making it challenging to
quantify the dose for each process. A broad spectrum for drug quantifi-
cation is required to avoid unwanted biological processes.
In our study, we chose As2O3, a popular chemotherapeutic agent in a
variety of cancer treatments. As2O3 has been investigated as a potential
sensitizer of cancer stem cells for possible modality to treat Glioblastoma
Multiforme (GBM) (Tomuleasa et al. 2010). The methodology exploits
the effects of radiation and chemotherapy to treat inoperable GBM.
Scientists have reported an increase cure rate when As2O3 and radiation
therapy were used concurrently (Ning and Knox 2004). Enhanced effects
of As2O3 such as therapeutic efficiency with radiation have also been
reported in oral squamous carcinoma (Kumar et al. 2008). Other
researchers reported an increased killing rate of human fibrosarcoma
cells with As2O3 in both in vitro and in vivo settings (Chiu et al. 2010).
One advantage of As2O3 is its capability to penetrate into the subcellular
compartments of living cells (Bacquart et al. 2010).
In our research, a wide dilution range of As2O3 was tested on highly
malignant breast cancer cells (Goswami et al. 2004; Raja et al. 2010; Raof
et al. 2011; Xue et al. 2006) (MTLn3). The cells were treated with lower
concentrations of As2O3 in combination with ionizing radiation. The inhi-
bition in cell growth and stimulation in cell proliferation was observed in
various dose ranges of As2O3. Quantification of the drug amount to pro-
duce different dose responses will open new opportunities in clinical
practice. The conventional clinical practice is heavily based on the MTD
model. The MTD methodology later induces severe side effects due to
necrotic processes. That is why clinicians are now exploring alternative
methods to MTD.
2 MATERIALS AND METHODS
2.1 Cell line and culture
MTLn3 rat mammary adenocarcinoma cells (from Dr. John
Condeelis) were cultured in alpha minimum essential medium (αMEM)
medium (Invitrogen Corporation, Carlsbad, CA). The medium was sup-
plemented with 5% fetal bovine serum (FBS) (Gemini Bio-Products, West
Sacramento, CA), 0.2% Sodium Bicarbonate (Sigma-Aldrich, St. Louis,
MO), and penicillin / streptomycin (Gibco / Invitrogen Corporation
MTLn3 cells, As2O3 and ionizing radiation
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Carlsbad, CA). The cells were kept at 37°C under humid conditions with
5% carbon dioxide. In all experiments, the cells were used between pas-
sages 5 and 12.
2.2 Arsenic trioxide preparation and dilutions
As2O3 99.0% pure, powder (Sigma-Aldrich, St. Louis, MO) was dis-
solved in boiling deionized water (diH2O) for 40 minutes. The solution
was then cooled to room temperature and filtered with a 0.22 µm filter.
The starting weight of As2O3 was subtracted from the un-dissolved As2O3
and final volume of diH2O was measured to determine the bulk concen-
tration of As2O3 in water (i.e. 50mM). As2O3 solution was then diluted in
cell culture media by the serial dilution technique. The concentrations of
As2O3 used on MTLn3 cells are discussed in the cell treatment section of
materials and methods.
2.3 Ionizing radiation and experimental setup
MTLn3 cells were irradiated with various doses of ionizing radiation
using a 6 Mega electron Volt (MeV) beam. The cells were cultured in 96-
well plates and placed at dmax (depth of maximum dose) and the dose
was delivered with the following settings; cone size 6x10 cm2, Source to
Surface Distance (SSD) = 100 cm and cell at dmax of 1.13 cm MTLn3 cells
treated with various concentrations of As2O3 were exposed to a standard
a therapeutic radiation dose of 200 centi Gray (cGy), while untreated
cells were exposed to 65 cGy, 120 cGy, 265 cGy and 330 cGy one dose per
day for successive days, respectively.
2.4 Cell treatment
MTLn3 Cells were seeded at a density of approximately 2500 cells per
well in transparent 96 well plates (Corning, Inc. Corning, NY) overnight
and then treated with ionizing radiation and As2O3. The serial dilutions
of As2O3 (20 µM to 1.22 nM) were administered as As2O3 alone and As2O3
with ionizing radiation together, and a group treated with ionizing radia-
tion alone. The doses of ionizing radiation (mentioned above) were deliv-
ered to specific dishes at 8, 24 and 48 hour time points (one dose per
day). Each condition and concentration of As2O3 was replicated 5 times
per experiment and repeated 3 times.
2.5 Cell proliferation assay
Cellular responses to various treatments were quantified by a cell via-
bility assay, in which the mitochondrial activity of live cells was measured
using premixed WST-1 cell proliferation assay (Clontec Inc. Mountain
View, CA) following manufacturer’s protocol. Briefly, tetrazolium salt was
reduced to formazan by mitochondria succinate-tetrazolium reductase
W. K. Raja and others
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present in living cells. As cells keep proliferating, the amount of these
enzymes would increase, reflective of the number of metabolically active
cells in culture. The plates treated under different conditions were incu-
bated with tetrazolium salt for 1 hour and absorption was measured at
440 nm with background absorption at 650 nm using microplate reader
(BioTek, Winooski, VT). The data from all the wells were normalized with
the control (untreated cells).
2.6 Apoptosis assay
Cellular apoptosis was measured using a terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) assay from R&D system
(Minneapolis, MN) to detect the DNA fragments in apoptotic cells. The
TUNEL assay used in a 96 well format according to the manufacturer’s
protocol. Briefly, cells were washed and fixed in formaldehyde solution
then treated with CytoninTM solution. After the removal of CytoninTM and
wash steps, MTLn3 cells were treated with hydrogen peroxide solution for
approximately 5 minutes and then washed in diH2O. Terminal deoxynu-
cleotidyl transferase (TdT) solution was added to each well followed by
centrifugation. Then, the supernatant was discarded and labeling reac-
tion mix was added. The reaction was halted with TdT stop buffer fol-
lowed by two rinse steps and then, the cells were treated with
biotin/streptavidin-horseradish peroxidase. Finally, the substrate solution
was added in each well after rinsing steps and the reaction kinetics was
measured at 630 nm. The reaction was stopped using 0.2 N HCl solution
per well and the absorption was measured at 450 nm.
2.7 Cell death assay
MTLn3 cell death was measured by quantifying the presence of lac-
tate dehydrogenase in the medium containing dead cells. The cells were
cultured overnight then treated with different conditions as mentioned
above. On the day of measurement, the treated cells were centrifuged in
96 well plates and supernatants were carefully transferred to new 96 well
plates, and LDH cytotoxicity detection reagents (Clontec Inc. Mountain
View, CA) were added to each well per manufacturer’s instructions.
Measured values from each well were normalized with the control
(untreated cells) and plotted.
3 RESULTS
3.1 Effects of hormesis induced by arsenic trioxide
MTLn3 cells have shown resistance to available chemotherapy drugs
(Goswami et al. 2004). The over expression of epidermal growth factor
(EGF) receptor make them highly sensitive to chemoattractant (i.e. EGF)
signals in their surroundings (Xue et al. 2006), which makes them more
MTLn3 cells, As2O3 and ionizing radiation
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sensitive to more subtle chemical gradients resulting in high metastatic
ability. When these cells were treated with various concentrations of inor-
ganic arsenic trioxide, apoptosis and hormesis effects were observed. In
the first 8hrs of arsenic trioxide (from 20 µM to 1.25 µM) treatment, a
slight decline in cell proliferation was observed due to the cytotoxic effect
of the drug, which was more pronounced in 24 and 48 hour time periods,
as shown in Figure 1A. The rapid proliferation of MTLn3 cells or horme-
sis was observed in the dose range from 0.625 µM to 78.1 nM, which was
more obvious at 48 hrs time period as compared to 24 hrs while in early
events (4 to 12 hrs), hormesis effect was not that evident. Figure 1A shows
that the MTLn3 cells, when treated with low concentration of arsenic tri-
oxide, showed proliferation rates similar to untreated cells. The cell pro-
liferation assay was based on the mitochondrial activities of the cells and
a DNA based assay was used as an alternative technique to verify these
results (shown in Figure 1B). These results confirmed that arsenic triox-
W. K. Raja and others
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FIGURE 1. A) Cancer cell proliferation (mitochondrial activity based assay) treated with various dilu-
tion of arsenic trioxide for 2 days. B) DNA bases cell proliferation assay treated with arsenic trioxide
dilutions for 2 days. C) Phase contrast images of MTLn3 cancer cells at different time points (24 hr
and 48 hr) after treated with arsenic trioxide. (Error bars represent mean data ± standard deviation). 
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ide was not only increasing the proliferation rate of these cells in the
hormesis region (1.25µM – 78nM) by increasing the total number of cells
(shown in Figure 1B, C) but stimulating the mitochondrial activity as well
as shown in Figure 1A. Figure 1C are the representative images collected
from these cells at different time points, verifying the increase in number
of cells at low concentration of arsenic trioxide.
3.2 An extended effect of hormesis induced by a combination of arsenic
trioxide and ionizing radiation
Ionizing radiation (i.e. electron beam with an energy of 6 MeV) is one
of the most common radiotherapy techniques used for cancer patients.
MTLn3 cells were exposed to various doses of 6 MeV electron beam i.e.
from 65 cGy to 330 cGy one dose per day for two days at 24 hour time
intervals. The maximum exposure of ionization radiation was performed
in two day periods, which showed little or no effect on these cells. The
proliferation profile of MTLn3 exposed to ionizing radiation is shown in
Figure 2A which indicates the cells are growing normally after exposure
to various doses of radiation. These results led us to combine the ionizing
radiation with arsenic trioxide treatment. It was expected that the arsenic
trioxide would disrupt the DNA repair process caused by the ionization
radiation. Figure 2B shows the proliferation activity of MTLn3 cells treat-
ed with both arsenic trioxide and ionization radiation (200cGy). Both cel-
lular death and stimulation in growth were observed in these experi-
ments similar to arsenic trioxide treated cells (Figure 1). Cellular growth
was arrested in the range from 20 µM to 1.25 µM, while an increase in cel-
lular proliferation was observed in concentration of arsenic trioxide
lower than 1.25 µM. The hormesis signal in this treatment was as high as
in the cells treated with arsenic trioxide alone. Interestingly on day two
the cells treated with low dilution of arsenic trioxide and ionization were
MTLn3 cells, As2O3 and ionizing radiation
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FIGURE 2. A) MTLn3 cancer cells response to 6 MeV electron beam ionization radiation at 24 hr and
48 hr without arsenic trioxide treatment. B) Proliferation of cancer cell treated both with arsenic tri-
oxide and electron beam ionization radiation. (Error bars represent mean data ± standard deviation). 
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proliferating more than normal. It is possible that low chemical treatment
with cytotoxic agents stressed the cells and when combined with another
stressing element (i.e. ionizing radiation), it inhibited cell death,
increased survival and stimulated cell proliferation.
Under conditions of arsenic trioxide treatment or a combination of
arsenic trioxide and ionization radiation treatment, an arrest and stimu-
lation in cell proliferation was observed at various levels of drug treat-
ment. These behaviors were verified by both the mitochondrial activities
and DNA analysis of the cells. To further quantify the level of apoptosis in
these cells, fragments of the DNA were measured using the TUNEL assay.
Apoptosis was measured after 48 hr of treatment in both conditions. The
cells treated with 10 µM of arsenic trioxide alone and in combination with
ionizing radiation showed the highest levels of apoptosis as seen in
Figure 3 while nuclease treatment was a positive control. In the hormesis
region (0.31 µM) a negligible level of apoptosis was observed in those
cells as compared to the untreated cells (Figure 3). The cells treated with
low concentration of arsenic trioxide such as 19 nM showed a slight
increase in the mean value of the apoptosis signal relative to untreated
cells as indicated in Figure 3. These results suggest that the chemical
treatment alone has dual effects on MTLn3 cells but the cells treated with
combination of ionizing radiation and the chemical showed no signifi-
cant difference on the cells proliferation behavior relative to chemical
treatment alone.
These results were also confirmed by measuring cell death in the
whole range of arsenic trioxide treatment with and without ionization
radiation. Figure 4 showed that at high concentrations of arsenic trioxide
treatment (i.e. 20 µM – 1.25 µM), most of the cells died. However, at low
concentrations (below 78 nM), cellular death was observed and the
W. K. Raja and others
36
FIGURE 3. Apoptosis measurements from MTLn3 cancer cells treated under different conditions for
48 hours with negative control (untreated cells) and positive control (nuclease treated cells). * and
# belong to different groups, on the bases of 95% confidence interval using ANOVA, (Error bars rep-
resent mean data ± standard deviation). 
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results were consistent with the TUNEL assay. No significant effect was
observed between ionization treated and untreated cells at lower con-
centrations of arsenic trioxide. The minimum level of cell death was
recorded in the hormesis region and at 0.31 µM, almost no cell death was
recorded as shown in Figure 4.
4 DISCUSSION
Conventional dosimetry protocols based on maximum tolerable dose
(MTD) are constantly challenged by the fact that surviving patients are
developing secondary cancers, among other problems. A certain dose
may be stimulatory to immune cells, an effect that is highly undesirable
in malignant cells. Likewise, an apoptosis-inducing dose is required to
treat unwanted cells, but the same effects on normal cells would be dis-
astrous. Quantification of dosing is therefore necessary to establish the
delicate thresholds of separating different competing phenomena in the
low dose region. This quantification is needed for different drugs in dif-
ferent cell lines to draw some standards.
One would argue that one size does not fit all as a given dose may
induce apoptosis in a robust individual while induce necrosis in a com-
promised one. However, a dose response will form a fundamental index
in clinical dosimetry, and the dose-response character of the cell biology
is a strong index to consider in any clinical setting. Since inhibition and
stimulation processes can occur in neighboring regions of narrow win-
dows of different concentrations, quantitative measurements are neces-
sary to specify these dosimetric parameters. In the case of As2O3, its dual
and opposing effects have been established. These can be due to genetic,
epigenetic factors or metabolism of the drug (Cui et al. 2008; Platanias
2009). Hormesis is a phenomenon of stimulatory effects whereas apop-
tosis is the altruistic suicide or self sacrifice by a cell. Both are useful ther-
MTLn3 cells, As2O3 and ionizing radiation
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FIGURE 4. LDH based cell death measurement response of MTLn3 cancer cells treated with various
dilutions of arsenic trioxide alone and in combination with ionizing radiation for 24 hours and 48
hours. (Error bars represent mean data ± standard deviation). 
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apeutic modalities based on their intended biological targets; however,
one may be desirable in one patient while at the same time the induction
of the other may prove disastrous or even fatal. Hence, there is a need to
further quantify these phenomena.
Various authors have investigated the specific dose for hormesis.
Hormesis is a useful biological phenomenon. For example, different car-
diac chemo-preventative effects of resveratrol have been reported due to
hormesis (Juhasz et al. 2010). Hormesis is a universal phenomenon found
across all living species. The radiation-induced cellular stress-resistance
mechanisms have been found with different genetic background in
Drosophila of both sexes (Moskalev et al. 2011). Hence, hormesis is a
genetic as well as sex dependent phenomenon. The hormetic effects of
individual chemicals as well as of mixtures have been found in different
experiments (Belz et al. 2008; Ge et al. 2010). However, the phenomenon
of chemical hormesis that exists in the presence of ionizing radiation in
the same dose window is reported here for the first time. This shows that
hormesis is a universal phenomenon that exists under different sets of
conditions or combined onslaughts of different modalities, such as radia-
tion and chemicals together. Radiation-induced hormesis is not inhibited
by chemicals or vice versa. It stands out in all forms of stresses.
Scientists are focused on firmly establishing dose standards in thera-
peutic drugs, among others. Although radiation alone does not produce
effects it enhances cell death in the presence of As2O3 in lower concen-
trations, verifying the presence of hormesis. The same drug at various
concentrations can produce different effects. Here, we documented that
inhibition and stimulation can be achieved by adjusting the dose ranges.
We found that the effects produce by certain concentrations of drugs can
exist even if the biological system is simultaneously exposed to an alter-
native treatment. We particularly observed that chemo and radiation
resistant cancer cells that respond to certain chemicals (e.g. As2O3) has
conserved responses (hormesis and apoptosis) even when exposed to
ionizing radiation. Cellular death that was observed between 20 µM and
2 µM of As2O3 concentration, while a higher concentration (>20 µM) can
also produce cell death, but may have other side effects in vivo. The pres-
ent study is focused to cell response in in vitro setting. However, it is pos-
sible that the lower dose can be tested and quantified by the same
methodology of Kim (Kim et al. 2008), which assumes the same range of
drug (i.e. drug/kg, for example 10 µmol/kg) will produce the same
effect (apoptosis) as seen in vitro.
5 CONCLUSIONS
Arsenic trioxide is an emerging chemotherapeutic reagent for solid
tumors and is already in use (clinically) for other types of cancers. We
evaluate arsenic trioxide on a highly metastatic, multidrug resist breast
W. K. Raja and others
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cancer cell line from solid tumors. Our results showed that arsenic triox-
ide was able to generate apoptosis in these cells; however, in lower doses
treatment with arsenic trioxide causes rapid cell proliferation. The
hormesis peak was recorded when cells were challenged with approxi-
mately 0.3 µM of arsenic trioxide. This effect disappeared at lower con-
centrations of arsenic trioxide. Although ionizing radiation alone had no
effect on cell proliferation, when combined with the low concentration
treatment of arsenic trioxide which alone had no effect, cellular prolifer-
ation was stimulated. Cellular death was observed on both sides of the
hormesis peak.
Further research is warranted to benchmark the dose amount
(dosimetry) for apoptosis and hormesis processes. The apoptotic process
is highly desirable in malignant diseases. This technique can be used to
eradicate pathogens or viral infected mutated cells with minimal side
effects. On the other hand, a dose sufficient to produce hormesis may be
suitable to control the autoimmune diseases such as arthritis, allergies,
diabetes, lupus, etc. Since these phenomena are complementary, a wide
spectrum of diseases can be addressed with such dosimetry methods.
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